ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $12,300,000 | +16.1% | 751,804 | 0.0% | 2.16% | -10.8% |
| Q2 2022 | $10,593,000 | -62.2% | 751,804 | -35.0% | 2.42% | -63.4% |
| Q1 2022 | $28,018,000 | +188.0% | 1,156,817 | +177.5% | 6.62% | +106.6% |
| Q4 2021 | $9,729,000 | +40.5% | 416,817 | 0.0% | 3.21% | +27.4% |
| Q3 2021 | $6,923,000 | -33.0% | 416,817 | -1.7% | 2.52% | -40.8% |
| Q2 2021 | $10,337,000 | -7.3% | 423,817 | -2.0% | 4.25% | -9.6% |
| Q1 2021 | $11,154,000 | -53.7% | 432,317 | -4.0% | 4.70% | -45.4% |
| Q4 2020 | $24,074,000 | -9.9% | 450,317 | -30.5% | 8.61% | -23.9% |
| Q3 2020 | $26,723,000 | -5.8% | 647,833 | +10.6% | 11.32% | -10.6% |
| Q2 2020 | $28,380,000 | +11.3% | 585,517 | -3.0% | 12.66% | -18.2% |
| Q1 2020 | $25,499,000 | +15.6% | 603,517 | +17.0% | 15.46% | +15.6% |
| Q4 2019 | $22,065,000 | – | 515,788 | – | 13.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |